Hyderabad Telangana, India

Jaldu Ravikanth

This inventor holds 1 USPTO granted patent. Top assignee: Mylan Laboratories Limited. Active years: 2015.


Average Co-Inventor Count = 11.0

ph-index = 1


Company Filing History:


Years Active: 2015

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Jaldu Ravikanth: Innovator in Pharmaceutical Chemistry

Introduction

Jaldu Ravikanth is a notable inventor based in Hyderabad, Telangana, India. He has made significant contributions to the field of pharmaceutical chemistry, particularly in the development of novel processes for drug synthesis. His work is characterized by a commitment to innovation and excellence in the pharmaceutical industry.

Latest Patents

Jaldu Ravikanth holds a patent for the synthesis of Aliskiren. This invention provides a novel process for the preparation of the renin inhibitor Aliskiren and its derivatives, along with its pharmaceutically acceptable salts. The patent also includes novel intermediates used in the preparation of Aliskiren, showcasing his expertise in medicinal chemistry.

Career Highlights

Ravikanth is currently employed at Mylan Laboratories Limited, a leading global pharmaceutical company. His role involves research and development, where he applies his knowledge to create effective pharmaceutical solutions. His dedication to advancing drug development has made him a valuable asset to his team.

Collaborations

Throughout his career, Jaldu has collaborated with several talented professionals, including Rama Shankar and Vadali Lakshmana Rao. These collaborations have fostered a creative environment that encourages innovation and the sharing of ideas.

Conclusion

Jaldu Ravikanth is a distinguished inventor whose work in pharmaceutical chemistry has led to significant advancements in drug synthesis. His contributions, particularly in the synthesis of Aliskiren, highlight his commitment to innovation in the pharmaceutical industry.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to [email protected]
Loading…